WO2002000170A3 - Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic - Google Patents

Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic Download PDF

Info

Publication number
WO2002000170A3
WO2002000170A3 PCT/US2001/020444 US0120444W WO0200170A3 WO 2002000170 A3 WO2002000170 A3 WO 2002000170A3 US 0120444 W US0120444 W US 0120444W WO 0200170 A3 WO0200170 A3 WO 0200170A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
patients
radiosensitizers
targeted delivery
treatment
Prior art date
Application number
PCT/US2001/020444
Other languages
English (en)
Other versions
WO2002000170A2 (fr
Inventor
Ward Page Faulk
Original Assignee
Ward Page Faulk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ward Page Faulk filed Critical Ward Page Faulk
Priority to EP01950547A priority Critical patent/EP1305051A4/fr
Priority to IL15358601A priority patent/IL153586A0/xx
Priority to CA002414401A priority patent/CA2414401A1/fr
Priority to JP2002504953A priority patent/JP2004501171A/ja
Priority to US10/311,302 priority patent/US20040028686A1/en
Priority to AU2001271525A priority patent/AU2001271525A1/en
Publication of WO2002000170A2 publication Critical patent/WO2002000170A2/fr
Publication of WO2002000170A3 publication Critical patent/WO2002000170A3/fr
Priority to US11/952,181 priority patent/US20080095802A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne la diffusion ciblée de médicaments cytotoxiques : A) à des lymphocytes responsables du rejet de tissus transplantés, comme des reins, des coeurs ou des cellules de moelle osseuse. B) L'invention concerne l'utilisation d'un système non-toxique de diffusion existant naturellement afin de transporter de fortes concentrations de radiosensibiliseurs des cellules cancéreuses. C) L'invention concerne également la diffusion ciblée de médicaments en cas de diagnostic médical et de traitement du cancer.
PCT/US2001/020444 2000-06-28 2001-06-28 Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic WO2002000170A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP01950547A EP1305051A4 (fr) 2000-06-28 2001-06-28 Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medi
IL15358601A IL153586A0 (en) 2000-06-28 2001-06-28 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
CA002414401A CA2414401A1 (fr) 2000-06-28 2001-06-28 Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic
JP2002504953A JP2004501171A (ja) 2000-06-28 2001-06-28 Ａ）臓器が移植された患者における活性化されたリンパ球への、ｂ）放射線療法を受ける患者における、癌細胞への放射線増感剤としての、ｃ）癌の診断および治療における薬物担体としてのビタミン結合タンパク質中の、細胞毒の標的指向型送達
US10/311,302 US20040028686A1 (en) 2001-06-28 2001-06-28 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplated organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
AU2001271525A AU2001271525A1 (en) 2000-06-28 2001-06-28 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
US11/952,181 US20080095802A1 (en) 2000-06-28 2007-12-07 Targeted delivery of cytotoxic drugs A) to activated lymphocytes in patients iwth transplanted organs, B) as radiosensitizers to cancer cells in paients undergoing radiation therapy, and C) in vitaminpbinding proteins as drug carriers in the diagnosis and treatment of cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21438800P 2000-06-28 2000-06-28
US21442700P 2000-06-28 2000-06-28
US21438900P 2000-06-28 2000-06-28
US60/214,388 2000-06-28
US60/214,389 2000-06-28
US60/214,427 2000-06-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/952,181 Continuation US20080095802A1 (en) 2000-06-28 2007-12-07 Targeted delivery of cytotoxic drugs A) to activated lymphocytes in patients iwth transplanted organs, B) as radiosensitizers to cancer cells in paients undergoing radiation therapy, and C) in vitaminpbinding proteins as drug carriers in the diagnosis and treatment of cancer

Publications (2)

Publication Number Publication Date
WO2002000170A2 WO2002000170A2 (fr) 2002-01-03
WO2002000170A3 true WO2002000170A3 (fr) 2002-08-08

Family

ID=27395985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/020444 WO2002000170A2 (fr) 2000-06-28 2001-06-28 Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic

Country Status (6)

Country Link
EP (1) EP1305051A4 (fr)
JP (1) JP2004501171A (fr)
AU (1) AU2001271525A1 (fr)
CA (1) CA2414401A1 (fr)
IL (1) IL153586A0 (fr)
WO (1) WO2002000170A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404334A4 (fr) * 2001-05-15 2005-02-02 Faulk Pharmaceuticals Inc Administration ciblee de composes bioactifs pour le traitement du cancer
DE60213232T2 (de) 2001-05-15 2007-07-26 Faulk Pharmaceuticals, Inc., Indianapolis Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5000935A (en) * 1985-08-02 1991-03-19 Faulk Ward P Treatment method utilizing transferrin-radioiodine conjugate
US5108987A (en) * 1982-02-25 1992-04-28 Faulk Ward P Conjugates of proteins with anti-tumor agents
US6150341A (en) * 1998-06-12 2000-11-21 Biotch Australia Pty Limited Vitamin B12 derivatives and methods for their preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US5208021A (en) * 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5792458A (en) * 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
CA2016584C (fr) * 1989-05-17 1999-06-29 Robert S. Greenfield Conjugats d'anthracycline ayant un nouvel adapteur et methodes de production

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108987A (en) * 1982-02-25 1992-04-28 Faulk Ward P Conjugates of proteins with anti-tumor agents
US5000935A (en) * 1985-08-02 1991-03-19 Faulk Ward P Treatment method utilizing transferrin-radioiodine conjugate
US6150341A (en) * 1998-06-12 2000-11-21 Biotch Australia Pty Limited Vitamin B12 derivatives and methods for their preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KISHIMOTO, T. ET AL.: "Receptors for transferrin and transcobalamin II display segregated distribution on microvilli of leukemia L1210 cells", BIOCHEM. BIPHYS. RES. COMMUN., vol. 146, no. 3, 14 August 1987 (1987-08-14), pages 1102 - 1108, XP002950815 *
WOODWARD ET AL.: "Enhanced allograft survival via simultaneous blockade of transferrin receptor and interleukin-2 receptor", TRANSPLANTATION, vol. 68, no. 9, 15 November 1999 (1999-11-15), pages 1369 - 1376, XP002950816 *

Also Published As

Publication number Publication date
JP2004501171A (ja) 2004-01-15
IL153586A0 (en) 2003-07-06
EP1305051A2 (fr) 2003-05-02
AU2001271525A1 (en) 2002-01-08
WO2002000170A2 (fr) 2002-01-03
EP1305051A4 (fr) 2007-01-10
CA2414401A1 (fr) 2002-01-03

Similar Documents

Publication Publication Date Title
EP2301531A3 (fr) Combinaisons et modes d'administration d'agents therapeutiques et traitement combine
WO2005044365A3 (fr) Therapie par l'intermediaire d'une administration ciblee de particules a nano-echelle
EP2332542A3 (fr) Utilisation de composes renfermant du methylol pour la fabrication d'un medicament pour traiter des tumeurs
EP1586338A3 (fr) Utilisation d'antioxydants pour la prévention d'oxydation et la réduction de la dégradation des principes actifs dans les articles médicaux libérant des principes actifs
EP2548880A3 (fr) Compositions pour augmenter l'activité de la télomérase
AR042795A1 (es) Fluidos de dialisis biocompatibles que contienen icodextrinas
ES2136673T3 (es) Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos.
WO2003084470A3 (fr) Compositions et procedes pour apport biologique cible de porteurs moleculaires
WO2005113720A3 (fr) Technique pour la conception de medicaments anticancereux specifiques au patient
EP1706145A4 (fr) Autoanticorps utilises comme excipients avec des composes pharmaceutiques utilises dans l'imagerie tumorale et le traitement du cancer
WO2020222866A1 (fr) Utilisation thérapeutique et prophylactique de mitochondries et d'agents mitochondriaux combinés
RU2335539C2 (ru) Фармацевтический препарат и способ лечения злокачественных опухолей у человека с помощью аргининовой депривации
WO2002000170A3 (fr) Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic
EP1226822A3 (fr) Promoteurs de la production de l'oxyde d'azote et de la NO synthéthase, compositions cosmétiques et pharmaceutiques les contenant
HUP0401188A2 (hu) Hiperelágazásos amilopektin sebészeti, gyógyító vagy diagnosztikai eljárásokban emlősöknél való alkalmazásra, különösen plazmatérfogat-növelőként
WO2002094199A3 (fr) Procede d'augmentation des niveaux d'anticorps anti-neugc dans le sang
MD2211G2 (ro) Remediu pentru tratamentul afecţiunilor periodonţiului
WO1997038700A1 (fr) Atmosphere enrichie en oxygene permettant d'accroitre la duree de vie efficace d'agents d'apport d'oxygene
WO2005028608A3 (fr) Processeur de cellules servant a traiter des maladies
CN114848836B (zh) 一种偶联物及其在治疗内耳疾病上的应用
Kolb et al. Dose rate and fractionation of total body irradiation in dogs: short and long term effects
Kasakura Great contributions of E. Donnall Thomas to the development of clinical applications of bone marrow transplantation, leading to the 1990 Nobel Prize in Medicine/Physiology
SE0401066D0 (sv) Chemical Derivatives
Muramatsu et al. Treatment strategy for recurrent and refractory epithelial ovarian cancer: efficacy of high-dose chemotherapy with hematopoietic stem cell transplantation
RU2349324C2 (ru) Способ комплексного лечения сарком мягких тканей

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 153586

Country of ref document: IL

Ref document number: 2414401

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10311302

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001271525

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001950547

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001950547

Country of ref document: EP